128 results on '"Farag, Sherif S."'
Search Results
102. Pre-Treatment Cytogenetics Predict Complete Remission and Long-Term Outcome in Patients (Pts) ≥60 Years with Acute Myeloid Leukemia (AML): Results from Cancer and Leukemia Group B (CALGB) 8461.
103. Single Institution Experience with Two High-Dose Chemotherapy (HDC) Conditioning Regimens Prior to Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma (MM).
104. New directions in natural killer cell-based immunotherapy of human cancer
105. The Therapeutic Use of Natural-Killer Cells in Hematological Malignancies.
106. Lack of In Vitro Cross-Reactivity Predicts Safety of Low-Molecular Weight Heparins in Heparin-Induced Thrombocytopenia
107. The potential role of PD0332991(Palbociclib) in the treatment of multiple myeloma
108. Treating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristine.
109. Differential stem- and progenitor-cell trafficking by prostaglandin E2 .
110. Fatal disseminated Scedosporium inflatum infection in a neutropenic immunocompromised patient
111. Increased mobilization and yield of stem cells using plerixafor in combination with granulocytecolony stimulating factor for the treatment of non-Hodgkin's lymphoma and multiple myeloma.
112. Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma.
113. Blood progenitor cell separation from clinical leukapheresis product by magnetic nanoparticle binding and magnetophoresis.
114. THE AUTHOR REPLIES.
115. FCGR3Aand FCGR2Apolymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia
116. Depletion of alloreactive T cells: which cell?
117. The Novel Aurora Kinase Inhibitor ENMD-2076 Has Potent Single Agent Activity against Multiple Myeloma (MM) in Vitroand in Vivo, and Shows Synergistic Activity in Combination with Lenalidomide
118. OSU-HDAC42, a Novel Histone Deacetylase Inhibitor, Induces Apoptosis in a Caspase-Dependent Manner and Induces p21WAF1/CIP1and p16 Expression in Multiple Myeloma Cell Lines.
119. Low CD34+ Cell Doses Are Associated with Increased Cost and Worse Outcome after Tandem Autologous Stem Cell Transplantation in Patients with Relapsed or Refractory Germ Cell Tumors.
120. Differential stem- and progenitor-cell trafficking by prostaglandin E2 .
121. Sitagliptin for Prophylaxis of Acute Graft-versus-Host Disease. Reply.
122. The potential role of PD0332991 (Palbociclib) in the treatment of multiple myeloma.
123. Increased mobilization and yield of stem cells using plerixafor in combination with granulocyte-colony stimulating factor for the treatment of non-Hodgkin's lymphoma and multiple myeloma.
124. Immunotherapeutic strategies of stem cell transplant in lymphoma.
125. Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B study.
126. Cytokine modulation of the innate immune system in the treatment of leukemia and lymphoma.
127. Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.
128. Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.